DR. LESLIE J RAFFEL, M.D.
Medical Practice at Beverly Blvd, Los Angeles, CA
License number
California G044711
Category
Medical Practice
Type
Pediatrics
Address
Address
8700 Beverly Blvd, Los Angeles, CA 90048
Phone
(310) 423-9914
(310) 423-2080 (Fax)
(310) 423-2080 (Fax)
Personal information
See more information about LESLIE J RAFFEL at radaris.comName
Address
Phone
1622 S Canfield Ave, Los Angeles, CA 90035
1622 Canfield Ave, Los Angeles, CA 90035
1419 Peerless Pl, Los Angeles, CA 90035
Organization information
See more information about LESLIE J RAFFEL at bizstanding.comLeslie J Raffel MD
8700 Beverly Blvd, West Hollywood, CA 90048
Categories:
Physicians & Surgeons
Phone:
(310) 423-3277 (Phone)
Leslie J Raffel MD
8723 Gracie Allen Dr #240, Los Angeles, CA 90048
Categories:
Physicians & Surgeons
Phone:
(310) 423-9914 (Phone)
Dr. Leslie J. Raffel, MD
8635 W 3 St, Los Angeles, CA 90048
Status:
Inactive
Industry:
Medical Doctor's Office
Principal:
Leslie Raffel Principal, inactive
Professional information
Method Of Haplotype-Based Genetic Analysis For Determining Risk For Developing Insulin Resistance, Coronary Artery Disease And Other Phenotypes
US Patent:
2004007, Apr 22, 2004
Filed:
Jun 16, 2003
Appl. No.:
10/463301
Inventors:
Kent Taylor - Ventura CA, US
Jerome Rotter - Los Angeles CA, US
Huiying Yang - Cerritos CA, US
Willa Hsueh - Pacific Palisades CA, US
Xiuqing Guo - Santa Monica CA, US
Leslie Raffel - Los Angeles CA, US
Mark Goodarzi - Loa Angeles CA, US
Jerome Rotter - Los Angeles CA, US
Huiying Yang - Cerritos CA, US
Willa Hsueh - Pacific Palisades CA, US
Xiuqing Guo - Santa Monica CA, US
Leslie Raffel - Los Angeles CA, US
Mark Goodarzi - Loa Angeles CA, US
International Classification:
C12Q001/68
US Classification:
435/006000
Abstract:
Disclosed is a method for determining haplotypes useful for large-scale genetic analysis, within a genomic reference sequence of interest, for a human subpopulation. The method can applied to statistically evaluating the genotypes of subjects for any statistically significant association with a phenotype of interest, such as insulin resistance or coronary artery disease. Thus, also disclosed are a method of detecting a genetic predisposition in a Mexican-American human subject for developing insulin resistance and methods of detecting a lower than normal risk in a Mexican-American human subject for developing insulin resistance or coronary artery disease.
Method Of Haplotype-Based Genetic Analysis For Determining Risk For Developing Insulin Resistance, Coronary Artery Disease And Other Phenotypes
US Patent:
8178294, May 15, 2012
Filed:
Nov 28, 2006
Appl. No.:
11/564243
Inventors:
Kent D. Taylor - Ventura CA, US
Jerome I. Rotter - Los Angeles CA, US
Huiying Yang - Hockessin DE, US
Willa A. Hsueh - Pacific Palisades CA, US
Xiuqing Guo - Santa Monica CA, US
Leslie J. Raffel - Los Angeles CA, US
Mark O. Goodarzi - Los Angeles CA, US
Jerome I. Rotter - Los Angeles CA, US
Huiying Yang - Hockessin DE, US
Willa A. Hsueh - Pacific Palisades CA, US
Xiuqing Guo - Santa Monica CA, US
Leslie J. Raffel - Los Angeles CA, US
Mark O. Goodarzi - Los Angeles CA, US
Assignee:
Cedars-Sinai Medical Center - Los Angeles CA
International Classification:
C12Q 1/68, C12P 19/34
US Classification:
435 61, 435 912
Abstract:
Disclosed is a method for determining haplotypes useful for large-scale genetic analysis, within a genomic reference sequence of interest, for a human subpopulation. The method can applied to statistically evaluating the genotypes of subjects for any statistically significant association with a phenotype of interest, such as insulin resistance or coronary artery disease. Thus, also disclosed are a method of detecting a genetic predisposition in a human subject for certain biological conditions, which may be related to coronary artery disease.
Director, Clinical Research Center At Cedars-Sinai Medical Center
Position:
Director, Clinical Research Center at Cedars-Sinai Medical Center
Location:
Greater Los Angeles Area
Industry:
Hospital & Health Care
Work:
Cedars-Sinai Medical Center
-
Director, Clinical Research Center
Dr. Leslie Raffel, Los Angeles CA - MD (Doctor of Medicine)
Specialties:
Pediatrics, Clinical Genetics
Address:
Cedars Sinai Medical Genetics
116 N Robertson Blvd, Los Angeles 90048
(310) 423-9914 (Phone)
8700 Beverly Blvd, Los Angeles 90048
(310) 423-9914 (Phone)
116 N Robertson Blvd, Los Angeles 90048
(310) 423-9914 (Phone)
8700 Beverly Blvd, Los Angeles 90048
(310) 423-9914 (Phone)
Certifications:
Clinical Genetics, 1984, Pediatrics, 1983
Awards:
Healthgrades Honor Roll
Languages:
English, Spanish
Hospitals:
Cedars Sinai Medical Genetics
116 N Robertson Blvd, Los Angeles 90048
8700 Beverly Blvd, Los Angeles 90048
Cedars - Sinai Medical Center
8700 West Beverly Blvd, West Hollywood 90048
116 N Robertson Blvd, Los Angeles 90048
8700 Beverly Blvd, Los Angeles 90048
Cedars - Sinai Medical Center
8700 West Beverly Blvd, West Hollywood 90048
Education:
Medical School
Medical College Of Pennsylvania
Graduated: 1978
St Christophers Hospital Chldn
Harbor UCLA Med Center
Medical College Of Pennsylvania
Graduated: 1978
St Christophers Hospital Chldn
Harbor UCLA Med Center
Methods Of Diagnosing Insulin Resistance And Sensitivity
US Patent:
2012008, Apr 12, 2012
Filed:
Oct 30, 2009
Appl. No.:
13/126695
Inventors:
Jerome I. Rotter - Los Angeles CA, US
Kent D. Taylor - Ventura CA, US
Xiuqing Guo - Santa Monica CA, US
Mark O. Goodarzi - Los Angeles CA, US
Leslie Raffel - Los Angeles CA, US
Thomas A. Buchanan - Los Angeles CA, US
Anny Xiang - Los Angeles CA, US
Kent D. Taylor - Ventura CA, US
Xiuqing Guo - Santa Monica CA, US
Mark O. Goodarzi - Los Angeles CA, US
Leslie Raffel - Los Angeles CA, US
Thomas A. Buchanan - Los Angeles CA, US
Anny Xiang - Los Angeles CA, US
Assignee:
CEDARS-SINAI MEDICAL CENTER - Los Angeles CA
International Classification:
C12Q 1/68
US Classification:
435 612
Abstract:
Methods of diagnosing susceptibility to metabolic insulin resistance and other related conditions are disclosed. The method provides means of diagnosing susceptibility to insulin resistance in Hispanic Americans by determining the presence of a risk haplotype at the LPL locus, the LPIN1 locus, and/or elevated levels of gamma-glutamyl transferase.